Movement Alert｜SPYRE THERAPEUTICS INC Rises 6.21% in Regular Trading, Trading at $89.915

Market Focus09-30 22:48

On September 30, SPYRE THERAPEUTICS INC rose 6.21% in regular trading, trading at $89.915/share, with turnover of $46.10 million.

Within the Biotechnology sector where SPYRE THERAPEUTICS INC belongs, individual stocks showed mixed performance. Among notable movers, Connect Biopharma Holdings Ltd. up 24.42%, Valion Bio Inc up 22.26%, Capricor Therapeutics up 13.19%, Kodiak Sciences Inc. up 0.42%, Moderna, Inc. down 5.95%.

SPYRE THERAPEUTICS INC is a clinical-stage biotechnology company focused on developing next-generation therapeutics for patients with inflammatory bowel disease. Its pipeline includes SPY001 (anti-a4b7), SPY002 (anti-TL1A), SPY003 (anti-IL-23), and multiple combination therapy candidates. Earlier this month, the company reported that SPY003 met the primary endpoint in its Phase 2 Skyline trial for ulcerative colitis, achieving a 20% clinical-remission rate and a 30% endoscopic-improvement rate at week 12, completing clinical proof-of-concept for all three components of its IBD strategy.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment